Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club
Drug Research
Return to: PBR Home | Drug Research
Today in Drug Research

Drug Research

FDA approves UCB's anti-epileptic drug Vimpat as monotherapy The US Food and Drug Administration (FDA) has granted approval for UCB's supplemental new drug application (sNDA) for Vimpat (lacosamide) C-V as monotherapy to treat partial-onset seizures in patients with epilepsy. Drug Research > Drug Delivery > News

Latest Drug Research News by Sector

Select a sector from the list or browse by sector below:

Drug Delivery

Johnson & Johnson announces major commitment to expedite ebola vaccine development
Johnson & Johnson (JNJ) has made a commitment of up to $200m to accelerate and significantly expand the production of an Ebola vaccine program in development at its Janssen Pharmaceutical Companies.
Oramed releases positive Phase IIa trial results with oral insulin in type 1 diabetes
By PBR Staff Writer
Oramed Pharmaceuticals has reported positive top-line clinical results from a Phase IIa clinical trial of its proprietary oral insulin capsules ORMD-0801, to treat type 1 diabetes.

Drug Discovery & Development

Vaxart accelerates Ebola tablet vaccine development
Vaxart, a privately held company developing vaccines that are administered by tablet rather than by injection, has announced that the company is accelerating its Ebola tablet vaccine program.
MabVax Therapeutics nominates HuMab 5B1 as lead clinical development candidate
MabVax Therapeutics Holdings, a clinical stage oncology drug development company, has formally nominated its HuMab 5B1 antibody as a clinical candidate for the diagnosis and treatment of pancreatic and colon cancer.